Skip to main content

Table 5 Summary of meta-analysis results

From: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis

Outcome

Study

Heterogeneity

ES (95%CI)

P

P(Egger)

P

I2(%)

ORR (%)

10

0.013

56.9

0.28(0.23,0.34)

0.000

0.268

DCR (%)

7

0.195

30.5

0.69(0.64,0.73)

0.000

0.068

mPFS(months)

7

0.001

73.1

5.87(4.96,6.78)

0.000

0.469

mOS(months)

3

0.137

49.7

19.35(17.53,21.17)

0.000

0.828

AEs (any grade, %)

6

0.000

92.8

0.90(0.85,0.95)

0.000

0.420

AEs (grade ≥ 3, %)

6

0.000

97.7

0.49(0.27,0.71)

0.000

0.250

  1. ORR the objective response rate, DCR the disease control rate, mPFS the median progression-free survival, mOS the median overall survival, AEs (any grade) any treatment-related adverse event (grade 1–2), AEs (grade ≥ 3) any treatment-related adverse event (grade 3–5)
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us